The one notable point in the article is that investors and analysts may be underestimating the sales potential of Botox for migraine, an indication approved by the FDA in Oct 2010 (#msg-55606649).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”